enGene Therapeutics Inc. — November 2026 Earnings Summary

Financial Performance:

• Cash balance as of October 31, 2026, was $245.8 million, providing operating flexibility through the potential BLA filing and approval.
• No revenue, earnings, profit margins, or cash flow figures were reported as the company is in the clinical development phase.
• No debt, deferred revenue, or other financial metrics were disclosed in the presentation.

Guidance and Future Outlook:

• Initiation of Biologics License Application (BLA) filing is planned for Q4 2026.
• Potential BLA approval decision and platform designation are expected in 2027.
• Data from the Surfactant Bladder Rinse cohort is anticipated in mid-2027.
• Management projects a potential net sales target of $1 billion with approximately 2,000 patients at a new price point.
• The new price point assumes a wholesale acquisition cost (WAC) of approximately $650,000–$700,000 per patient per year, resulting in a net price of $545,000 per year after a 21% gross-to-net discount.
• Payer coverage is expected at parity with new therapies assuming NCCN guideline category 2A designation.

Business Segments and Product Lines:

• Detalimogene Voraplasmid: The lead program is a non-viral gene therapy for non-muscle invasive bladder cancer (NMIBC).
• LEGEND Study Pivotal Cohort 1: Targeted BCG-unresponsive high-risk NMIBC with carcinoma in situ (CIS); fully enrolled with N=125 patients.
• Clinical Data (Pivotal Cohort 1, as of Oct 29, 2026):
  • Primary Endpoint (Any Time Complete Response): 56% (CI: 47%, 65%), compared to 54% in April 2026.
  • 12-Month Complete Response Rate: 24% (CI: 16%, 33%), compared to 13% in April 2026.
  • Duration of Response (DOR) ≥ 12 months: 43% (CI: 30%, 55%), compared to 25% in April 2026.
  • 100% of responders were free from progression to ≥T2 disease; 96% of responders remained free from cystectomy.
• Surfactant Cohort: A new cohort combining detalimogene with a 0.25% polidocanol surfactant bladder rinse has enrolled its first patients (target N=80).
  • Surfactant pretreatment reduces detalimogene dwell time from 60 minutes to 30 minutes.
  • Preclinical data showed >10x increase in gene expression and >9x increase in IL-12 expression with surfactant.
• Other LEGEND Cohorts: Active Phase 2 trials include BCG-Naïve/CIS, BCG-Exposed/CIS, and BCG-Unresponsive/Papillary Only cohorts.
• Manufacturing: Selected for the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program; utilizes proprietary DDX sugar polymer with low cost of goods and no specialized storage requirements (stable in fridge for months, freezer for years).

Market and Competitive Landscape:

• Market Size: Total Addressable Market (TAM) for high-risk BCG-unresponsive/exposed NMIBC is estimated at 40,000–75,000; BCG-naïve at 25,000–30,000; intermediate risk at 50,000–80,000, totaling 120,000+ patients.
• Patient Segmentation: 75% of BCG-unresponsive NMIBC patients are treated in community urology practices.
• Competitive Positioning: Detalimogene is the first and only non-viral investigational gene therapy for NMIBC.
• Comparative Efficacy (Any Time CR Rate): Detalimogene (56%) vs. Keytruda (41%), Adstiladrin (51%), Anktiva + BCG (62%), Inlexzo (82%), Cretostimogene (76%).
• Comparative Durability (DOR ≥ 12 Months): Detalimogene (43%) vs. Keytruda (46%), Adstiladrin (46%), Anktiva + BCG (58%), Inlexzo (51%).
• Market Dynamics: Patient sequencing is expected to expand the treatable population by 3,000–5,000 patients over time as patients move through 3rd and 4th-line therapies before radical cystectomy.
• Commercial Strategy: Field force planned for 40–60 representatives to cover 11,000 bladder cancer urologists.

Risks and Challenges:

• Regulatory Risk: No guarantee that detalimogene will successfully complete clinical development phases, achieve positive pivotal results, or receive BLA approval.
• Clinical Risk: Preliminary clinical data may not predict final trial results; ongoing data collection and cleaning may alter outcomes.
• Operational Risk: Challenges in recruiting and retaining personnel, establishing clinical sites, and enrolling patients.
• Market Risk: Uncertainty regarding market acceptance, payer coverage, and pricing parity.
• Forward-Looking Statements: Actual results may differ materially from projections due to risks beyond company control, including FDA decisions and trial outcomes.

Management Commentary and Tone:

• Management expressed confidence in the "unique non-viral offering" designed to redefine community care.
• CEO Ron Cooper highlighted the team's experience in developing and commercializing successful medicines.
• The tone emphasizes the product's potential to reduce patient burden (shorter dwell time, no urine bleaching) and logistical complexity (no freezer/thaw requirements) compared to BCG and other approved therapies.
• Management views the surfactant combination as a potential "best-in-class" opportunity to improve efficacy and durability while maintaining ease of use.

Analyst Questions and Answers:

• No analyst questions or answers were included in the provided presentation text.

Other Key Points:

• Intellectual Property: Comprehensive IP portfolio secured through at least 2040.
• Safety Profile: Treatment-related adverse events (TRAEs) were generally mild and reversible; 93% were Grade 1-2. Dose interruptions occurred in 4% of patients, and discontinuations in 1%.
• Platform Technology: The DDX platform allows for large genetic cargo, redosing, and low cost of goods without specialized handling.
• Team: The executive team includes former leaders from Albireo Pharma, Bristol Myers Squibb, Astellas, Ipsen, and Genentech.
• Market Research: Data relies on third-party sources including SEER database, American Urological Association, and internal claims analysis of >2,000 patient records.